Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383-390.

@article{Luo2017CommentON,
  title={Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383-390.},
  author={Kaiping Luo and Weidong Fang and Gaosi Xu},
  journal={Diabetes care},
  year={2017},
  volume={40 8},
  pages={e108}
}
Niewczas et al. (1) reported the associations between metabolomic determinants and the risk of end-stage renal disease (ESRD) in participants with type 1 diabetes. The study concluded that patients with elevated circulating levels of certain modified metabolites experienced faster renal function decline than other participants. The research is exciting… CONTINUE READING